WORK Medical (WOK) Technology announced that its subsidiary, Hunan Saitumofei received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence-Automated Human Blood Cell Morphology Analyzer. This regulatory approval represents a milestone in WORK Medical’s research and development strategy and is expected to position the Company’s new AI-driven device as a key growth catalyst.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WOK:
- Upcoming Stock Splits This Week (December 29 to January 2) – Stay Invested
- WORK Medical announces 1-for-100 reverse stock split
- Work Medical Technology Group Ltd trading resumes
- Work Medical Technology Group Ltd trading halted, volatility trading pause
- WORK Medical Technology Group Enters Sales Agreement to Raise $200 Million